Skip to main content

David Jayne

David Jayne, MD, FMedSci, is Professor of Clinical Autoimmunity at the University of Cambridge, UK, and Director of the Vasculitis and Lupus service at Addenbrooke’s Hospital Cambridge. He trained at the Universities of Cambridge and London, and in nephrology at Harvard Medical School, Boston, USA. He was a research fellow at Imperial College London and the University of Cambridge and was appointed as a Senior Lecturer in Nephrology at St George’s Hospital, London.He is a co-founder and the current President of the European Vasculitis Society and his research focus has been ANCA vasculitis and lupus nephritis, having led a sequence of international randomized controlled trials over the last 25 years. His research group conducts first into disease trials of newer immunosuppressives and biologics in vasculitis and lupus. He has published over 450 peer-reviewed papers and has contributed to numerous guideline statements. His work with industry has contributed to the approval of avacopan for ANCA-associated vasculitis and voclosporin for lupus nephritis. The clinical service in Cambridge cares for over 2000 patients with complex multi-system autoimmunity and receives tertiary referrals from throughout the UK and beyond. In 2021 he was awarded the ERA-EDTA prize for outstanding contributions to nephrology.


David Jayne receives consultancy fees from Astra-Zeneca, BMS, Boehringer-Ingelheim, Chemocentryx, GSK, NICE, Novartis, Otsuka, Roche/Genentech, Takeda, UCB, and Vifor; lecture fees from Amgen and Vifor; board member at Aurinia; commercial research grants from GSK and Roche/Genentech; and non-commercial research grants from EU, MRC, NIHR, and Versus Arthritis.


Latest contributions from David Jayne

Sebastian Sattui and David Jayne

28-01-2022 | COVID-19 | Video | Article

Rituximab use in the COVID-19 era: Striking the right balance

With rituximab-treated patients having an elevated risk for severe COVID-19 and a reduced likelihood of responding to vaccines, Sebastian Sattui and David Jayne discuss how these challenges can be addressed and explore the future role of the drug for the treatment of rheumatic diseases.